CANbridge Pharma appoints Richard Arthur Moscicki as independent director, remuneration committee chair

• Canbridge Pharmaceuticals named Richard Arthur Moscicki independent non-executive director effective Aug. 5, 2026.
• Moscicki also became remuneration committee chair, audit committee member.
• Richard James Gregory resigned as independent non-executive director, remuneration committee chair, audit committee member effective Aug. 5, 2026.
• Moscicki is a Reagan-Udall Foundation director; former FDA drug center deputy director for science operations; held senior roles at Genzyme.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260806-12274264), on August 05, 2026, and is solely responsible for the information contained therein.